After a year, 80% had moderate-or-less valve leakage with a repair device, versus 30% on medication.

Edwards Lifesciences (EW) reported positive results from its CLASP II TR trial, showing that the PASCAL system improved outcomes in tricuspid regurgitation patients. After one year, 80% of patients treated with the PASCAL system achieved moderate or less severe tricuspid regurgitation, compared with 30% in the control group. The company plans to announce Q3 2026 results on November 4, 2026, and EW stock closed at $93.26, up 1.36%.

Edwards Lifesciences (EW) reported Phase 3 PROGRESS trial results showing TAVR reduced risk of death or heart failure by 33% over 2 years vs. surveillance in moderate aortic stenosis patients. TAVR also improved quality of life and had a favorable safety profile. The trial enrolled 744 patients across 74 sites. EW stock closed at $93.26, up 1.36%.

Edwards Lifesciences reported positive results from two trials. The PASCAL CLASP IITR trial showed patients treated with PASCAL had nearly twice the benefit of those with medical therapy alone, with 80% having moderate or less tricuspid regurgitation at one year. The PROGRESS trial found TAVR reduced the two-year risk of death or heart-failure events by 33% in selected patients with moderate aortic stenosis.

Edwards Lifesciences (EW) announced that its PASCAL system for tricuspid repair met the primary goal in a trial, showing significant reduction in tricuspid regurgitation compared to medical therapy. The CLASP II TR study results were reported by the company.

Edwards Lifesciences (NYSE:EW) reported that its PASCAL system for tricuspid repair met its primary endpoint in the CLASP II TR trial, showing 80% of patients achieved moderate or less regurgitation at one year, compared to 30% in the control group. The trial also showed an 18-point improvement in quality-of-life measures. The PASCAL system received FDA approval in October 2026 and has been used to treat thousands of patients worldwide, according to the company.

Edwards Lifesciences reported that its PASCAL device met the primary endpoint in the CLASP II TR trial, with 80% of patients showing ≤ moderate tricuspid regurgitation at one year, compared to 30% in the control group. The company also noted improvements in quality-of-life scores. This follows the device's FDA approval in October 2026.